These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 27514841)

  • 21. Diverse
    Weigelt B; Comino-Méndez I; de Bruijn I; Tian L; Meisel JL; García-Murillas I; Fribbens C; Cutts R; Martelotto LG; Ng CKY; Lim RS; Selenica P; Piscuoglio S; Aghajanian C; Norton L; Murali R; Hyman DM; Borsu L; Arcila ME; Konner J; Reis-Filho JS; Greenberg RA; Robson ME; Turner NC
    Clin Cancer Res; 2017 Nov; 23(21):6708-6720. PubMed ID: 28765325
    [No Abstract]   [Full Text] [Related]  

  • 22. Secondary BRCA1 and BRCA2 alterations and acquired chemoresistance.
    Wang W; Figg WD
    Cancer Biol Ther; 2008 Jul; 7(7):1004-5. PubMed ID: 18720553
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In brief: BRCA1 and BRCA2.
    Foulkes WD; Shuen AY
    J Pathol; 2013 Aug; 230(4):347-9. PubMed ID: 23620175
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Twenty Years of BRCA1 and BRCA2 Molecular Analysis at MMCI - Current Developments for the Classification of Variants.
    Machackova E; Claes K; Mikova M; Házová J; Sťahlová EH; Vasickova P; Trbusek M; Navrátilová M; Svoboda M; Foretová L
    Klin Onkol; 2019; 32(Supplementum2):51-71. PubMed ID: 31409081
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The RAD52 S346X variant reduces risk of developing breast cancer in carriers of pathogenic germline BRCA2 mutations.
    Adamson AW; Ding YC; Mendez-Dorantes C; Bailis AM; Stark JM; Neuhausen SL
    Mol Oncol; 2020 Jun; 14(6):1124-1133. PubMed ID: 32175645
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Testing of mutations in BRCA1 and BRCA2 genes in tumor tissues - possibilities and limitations].
    Vošmiková H; Ryška A; Sieglová K; Laco J
    Cesk Patol; 2016; 52(4):210-214. PubMed ID: 27869447
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Minding the gap: the underground functions of BRCA1 and BRCA2 at stalled replication forks.
    Nagaraju G; Scully R
    DNA Repair (Amst); 2007 Jul; 6(7):1018-31. PubMed ID: 17379580
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic exploitation of tumor cell defects in homologous recombination.
    Powell SN; Kachnic LA
    Anticancer Agents Med Chem; 2008 May; 8(4):448-60. PubMed ID: 18473729
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers.
    Nones K; Johnson J; Newell F; Patch AM; Thorne H; Kazakoff SH; de Luca XM; Parsons MT; Ferguson K; Reid LE; McCart Reed AE; Srihari S; Lakis V; Davidson AL; Mukhopadhyay P; Holmes O; Xu Q; Wood S; Leonard C; ; ; ; Beesley J; Harris JM; Barnes D; Degasperi A; Ragan MA; Spurdle AB; Khanna KK; Lakhani SR; Pearson JV; Nik-Zainal S; Chenevix-Trench G; Waddell N; Simpson PT
    Ann Oncol; 2019 Jul; 30(7):1071-1079. PubMed ID: 31090900
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families.
    Cherbal F; Salhi N; Bakour R; Adane S; Boualga K; Maillet P
    Dis Markers; 2012; 32(6):343-53. PubMed ID: 22684231
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic targeting and patient selection for cancers with homologous recombination defects.
    Talens F; Jalving M; Gietema JA; Van Vugt MA
    Expert Opin Drug Discov; 2017 Jun; 12(6):565-581. PubMed ID: 28425306
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comprehensive literature review and meta-analysis of the prevalence of pan-cancer BRCA mutations, homologous recombination repair gene mutations, and homologous recombination deficiencies.
    Shao C; Wan J; Lam FC; Tang H; Marley AR; Song Y; Miller C; Brown M; Han J; Adeboyeje G
    Environ Mol Mutagen; 2022 Jul; 63(6):308-316. PubMed ID: 36054589
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BRCA1- and BRCA2-related mutations: therapeutic implications in ovarian cancer.
    Pothuri B
    Ann Oncol; 2013 Nov; 24 Suppl 8():viii22-viii27. PubMed ID: 24131965
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BRCA1, BRCA2, and TP53 germline and somatic variants and clinicopathological characteristics of Brazilian patients with epithelial ovarian cancer.
    Richau CS; Scherer NM; Matta BP; de Armas EM; de Barros Moreira FC; Bergmann A; Pereira Chaves CB; Boroni M; Dos Santos ACE; Moreira MAM
    Cancer Med; 2024 Feb; 13(3):e6729. PubMed ID: 38308422
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers.
    Osorio A; Milne RL; Kuchenbaecker K; Vaclová T; Pita G; Alonso R; Peterlongo P; Blanco I; de la Hoya M; Duran M; Díez O; Ramón Y Cajal T; Konstantopoulou I; Martínez-Bouzas C; Andrés Conejero R; Soucy P; McGuffog L; Barrowdale D; Lee A; ; Arver B; Rantala J; Loman N; Ehrencrona H; Olopade OI; Beattie MS; Domchek SM; Nathanson K; Rebbeck TR; Arun BK; Karlan BY; Walsh C; Lester J; John EM; Whittemore AS; Daly MB; Southey M; Hopper J; Terry MB; Buys SS; Janavicius R; Dorfling CM; van Rensburg EJ; Steele L; Neuhausen SL; Ding YC; Hansen TV; Jønson L; Ejlertsen B; Gerdes AM; Infante M; Herráez B; Moreno LT; Weitzel JN; Herzog J; Weeman K; Manoukian S; Peissel B; Zaffaroni D; Scuvera G; Bonanni B; Mariette F; Volorio S; Viel A; Varesco L; Papi L; Ottini L; Tibiletti MG; Radice P; Yannoukakos D; Garber J; Ellis S; Frost D; Platte R; Fineberg E; Evans G; Lalloo F; Izatt L; Eeles R; Adlard J; Davidson R; Cole T; Eccles D; Cook J; Hodgson S; Brewer C; Tischkowitz M; Douglas F; Porteous M; Side L; Walker L; Morrison P; Donaldson A; Kennedy J; Foo C; Godwin AK; Schmutzler RK; Wappenschmidt B; Rhiem K; Engel C; Meindl A; Ditsch N; Arnold N; Plendl HJ; Niederacher D; Sutter C; Wang-Gohrke S; Steinemann D; Preisler-Adams S; Kast K; Varon-Mateeva R; Gehrig A; Stoppa-Lyonnet D; Sinilnikova OM; Mazoyer S; Damiola F; Poppe B; Claes K; Piedmonte M; Tucker K; Backes F; Rodríguez G; Brewster W; Wakeley K; Rutherford T; Caldés T; Nevanlinna H; Aittomäki K; Rookus MA; van Os TA; van der Kolk L; de Lange JL; Meijers-Heijboer HE; van der Hout AH; van Asperen CJ; Gómez Garcia EB; Hoogerbrugge N; Collée JM; van Deurzen CH; van der Luijt RB; Devilee P; ; Olah E; Lázaro C; Teulé A; Menéndez M; Jakubowska A; Cybulski C; Gronwald J; Lubinski J; Durda K; Jaworska-Bieniek K; Johannsson OT; Maugard C; Montagna M; Tognazzo S; Teixeira MR; Healey S; ; Olswold C; Guidugli L; Lindor N; Slager S; Szabo CI; Vijai J; Robson M; Kauff N; Zhang L; Rau-Murthy R; Fink-Retter A; Singer CF; Rappaport C; Geschwantler Kaulich D; Pfeiler G; Tea MK; Berger A; Phelan CM; Greene MH; Mai PL; Lejbkowicz F; Andrulis I; Mulligan AM; Glendon G; Toland AE; Bojesen A; Pedersen IS; Sunde L; Thomassen M; Kruse TA; Jensen UB; Friedman E; Laitman Y; Shimon SP; Simard J; Easton DF; Offit K; Couch FJ; Chenevix-Trench G; Antoniou AC; Benitez J
    PLoS Genet; 2014 Apr; 10(4):e1004256. PubMed ID: 24698998
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Frequency of mutations in BRCA genes and other candidate genes in high-risk probands or probands with breast or ovarian cancer in the Czech Republic.
    Riedlova P; Janoutova J; Hermanova B
    Mol Biol Rep; 2020 Apr; 47(4):2763-2769. PubMed ID: 32180084
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status.
    Gadducci A; Guarneri V; Peccatori FA; Ronzino G; Scandurra G; Zamagni C; Zola P; Salutari V
    J Ovarian Res; 2019 Jan; 12(1):9. PubMed ID: 30691488
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BRCA1 and BRCA2 germline mutations screening in Algerian breast/ovarian cancer families.
    Cherbal F; Bakour R; Adane S; Boualga K; Benais-Pont G; Maillet P
    Dis Markers; 2010; 28(6):377-84. PubMed ID: 20683152
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures.
    Davies H; Glodzik D; Morganella S; Yates LR; Staaf J; Zou X; Ramakrishna M; Martin S; Boyault S; Sieuwerts AM; Simpson PT; King TA; Raine K; Eyfjord JE; Kong G; Borg Å; Birney E; Stunnenberg HG; van de Vijver MJ; Børresen-Dale AL; Martens JW; Span PN; Lakhani SR; Vincent-Salomon A; Sotiriou C; Tutt A; Thompson AM; Van Laere S; Richardson AL; Viari A; Campbell PJ; Stratton MR; Nik-Zainal S
    Nat Med; 2017 Apr; 23(4):517-525. PubMed ID: 28288110
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression and mutations of BRCA in breast cancer and ovarian cancer: Evidence from bioinformatics analyses.
    Wang Z; Zhang J; Zhang Y; Deng Q; Liang H
    Int J Mol Med; 2018 Dec; 42(6):3542-3550. PubMed ID: 30221688
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.